Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OmniSonics secures $26 million to further develop OmniWave:

This article was originally published in Clinica

Executive Summary

OmniSonics has raised $26m through third round financing to further develop its OmniWave technology platform. OmniWave, a technology that enables the delivery of acoustic energy over the active length of a small diameter wire in an occluded blood vessel, became available on the European market earlier this year and the Wilmington, Massachusetts-based company now has its sights set on the US. The technology's pre-clinical coronary data were presented at last month's Transcatheter Cardiovascular Therapeutics (TCT) meeting and the company's confidence in OmniWave's future is strong. President and CEO Robert Rabiner said that raising the finance "speaks to the promise" of the technology, and is looking forward to "advancing the product within multiple areas of the cardiovascular field". The financing is being led by new investor General Electric Pension Trust.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT063892

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel